TUSTIN, Calif., Oct 20, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced it will webcast the company review portions of its Annual Meeting of Stockholders to be held on October 24 at 10:30 am PDT. The webcast will begin with the voting results of the Annual Meeting and will be followed by presentations from Peregrine collaborators Drs. Philip Thorpe and Melina Soares, who will review the scientific progress of Peregrine's lead drug candidate Tarvacin™ in both anti-cancer and anti-viral indications. Mr. Steven King, Peregrine's president and CEO, will provide a company overview and update.

To access the webcast go to the Investor Relations section of the company website (www.peregrineinc.com) and click on the Annual Meeting webcast icon. The webcast will be archived on Peregrine's website for approximately 30 days.

About Peregrine

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and viral diseases. The company is pursuing three separate clinical trials in cancer and anti-viral indications with its lead product candidates Tarvacin™ and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Investors
Barbara Lindheim
GendeLLindheim BioCom Partners
(800) 987-8256
ir@peregrineinc.com

SOURCE Peregrine Pharmaceuticals, Inc.